Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

On August15, 2017, Onconova Therapeutics,Inc. (the “Company”) issued a press release announcing its financial results for the quarter and six months ended June30, 2017, a copy of which is attached hereto as Exhibit99.1 and incorporated herein by reference. The information contained in this Form8-K (including the exhibit hereto) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 2.02. Financial Statements and Exhibits

(d)Exhibits.

99.1 Press release issued by the Company dated August15, 2017.


Onconova Therapeutics, Inc. Exhibit
EX-99.1 2 a17-20159_1ex99d1.htm EX-99.1 Exhibit 99.1   Onconova Therapeutics,…
To view the full exhibit click here

About Onconova Therapeutics,Inc. (NASDAQ:ONTX)

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.